The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. As part of its… Read More
Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the… Read More
Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Read More
Meet Stunner: The One-Shot Protein Concentration and Sizing Combo Sponsored by Unchained Labs Stunner pulls double-duty so you don’t have to. It’s the one and only system that combines high-speed UV/Vis spectral analysis and Dynamic Light Scattering (DLS) for quantifying concentration and nailing down protein stability. Read More
The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it? Sponsored by BMGLabtech & CISBio Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the… Read More
Webinar date: Sponsored by BMG Labtech & CISBio #Webinars
Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver… Read More
Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70… Read More
New brand promise, new logo, new colors – Sartorius looks different today. A leading international partner of life science research and the biopharmaceutical industry, the company has revised its brand look. At the focus of this relaunch is Sartorius’ new brand promise that it summarizes in… Read More
PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical. PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative… Read More
Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019. New service reduces the risk, expenditure and time required for the later stages of antibody development Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and… Read More
Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption… Read More
TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has announced its corporate name change to SPT Labtech effective from January 6, 2020. The change of name is a contractual requirement of its divestment from… Read More
The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More
Grey Wolf Therapeutics completes £2.5 million ($3.3 million) Series A2 financing to accelerate development of therapies targeting ERAP2. Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery… Read More
Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients. Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of… Read More
State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford,… Read More